FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 9, 2011, Pages

  Weidinger, Carl ^a   Krause, Kerstin ^a   Mueller, Kathrin ^a   Klagge, Antje ^a   Fuhrer, Dagmar ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P110; SULINDAC SULFIDE; THREONINE; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME REGULATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; THYROID CELL; THYROID TUMOR; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOMA; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; ONCOGENES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION; SULINDAC; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 80052550914     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2010-2453     Document Type: Article

References (28)

1. Myatt S.S., Lam E.W. 2007 The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7:847-859 (Pubitemid 350006253)
2. Weidinger C., Krause K., Klagge A., Karger S., Fuhrer D. 2008 Forkhead box-O transcription factors: Critical conductors of cancer's fate. Endocr Relat Cancer 15:917-929
3. Dijkers P.F., Medema R.H., Pals C., Banerji L., Thomas N.S., Lam E.W., Burgering B.M., Raaijmakers J.A., Lammers J.W., Koenderman L., Coffer P.J. 2000 Forkhead transcription factor FKHR-L1 modulates cytokine- dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 20:9138-9148 (Pubitemid 32246103)
4. Furukawa-Hibi Y., Yoshida-Araki K., Ohta T., Ikeda K., Motoyama N.2002 FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress. J Biol Chem 277:26729-26732 (Pubitemid 34951676)
5. Brunet A., Kanai F., Stehn J., Xu J., Sarbassova D., Frangioni J.V., Dalal S.N., DeCaprio J.A., Greenberg M.E., Yaffe M.B. 2002 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol 156:817-828 (Pubitemid 34839865)
6. Paes J.E., Ringel M.D. 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-387, viii-ix (Pubitemid 351698084)
7. Guigon C.J., Zhao L., Willingham M.C., Cheng S.Y. 2009 PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 28:509-517
8. Ricate-Filho J.C., Ryder M., Clitale D.A., Rivera M., Heeguy A., Caday M., Janakirana M., Sollt D., Knauf J.A., Tuttle R.M., Ghossein R.A., Fagin J.A. 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Oncogene 69: 4885-4893
9. Karger S., Weidinger C., Krause K., Sheu S.Y., Aigner T., Gimm O., Schmid K.W., Dralle H., Fuehrer D. 2009 FOXO3a: A novel player in thyroid carcinogenesis? Endocr Relat Cancer 16:189-199
10. Miller K.A., Yeager N., Baker K., Liao X.H., Retetoff S., Di Cristofano A. 2009 Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 69:3689-3694
11. Liou J.Y., Ghelani D., Yeh S., Wu K.K. 2007 Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res 67:3185-3191 (Pubitemid 46724856)
12. Lee H.C., Park I.C., Park M.J., An S., Woo S.H., Jin H.O., Chung H.Y., Lee S.J., Gwak H.S., Hong Y.J., Yoo D.H., Rhee C.H., Hong S.I. 2005 Sulindac and its metabolites inhibit invasion of glioblastoma cells via downregulation of Akt/PKB and MMP-2. J Cell Biochem 94:597-610 (Pubitemid 41420295)
13. Stewart G.D., Nanda J., Brown D.J., Riddick A.C., Ross J.A., Habib F.K. 2009 NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer 124:223-232
14. Ambesi-Impiombato F.S., Parks L.A., Coon H.G. 1980 Culture of hormone- dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci USA 77:3455-3459 (Pubitemid 10012253)
15. Krause K., Karger S., Sheu S.Y., Aigner T., Kursawe R., Gimm O., Schmid K.W., Dralle H., Fuhrer D. 2008 Evidence for a role of the amyloid precursor protein in thyroid carcinogenesis. J Endocrinol 198:291-299
16. Flis S., Splwiński J. 2009 Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide. Anticancer Res 29:435-441
17. Joe A.K., Liu H., Xiao D., Soh J.W., Pinto J.T., Beer D.G., Piazza G.A., Thompson W.J., Weinstein I.B. 2003 Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells. J Exp Ther Oncol 3:83-94 (Pubitemid 36702521)
18. Marchetti M., Resnick L., Gamliel E., Kesaraju S., Weissbach H., Binninger D. 2009 Sulindac enhances the killing of cancer cells exposed to oxidative stress. PLoS One 4:e5804
19. Seo A.M., Hong S.W., Shin J.S., Park I.C., Hong N.J., Kim D.J., LeeW.K., Lee W.J., Jin D.H., Lee M.S. 2009 Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKβ. Apoptosis 14:913-922
20. Eszlinger M., Krohn K., Berger K., Läuter J., Kropf S., Beck M., Führer D., Paschke R. 2005 Gene expression analysis reveals evidence for increased expression of cell cycle-associated genes and Gq-proteinprotein kinaseCsignaling in cold thyroid nodules. J Clin Endocrinol Metab 90:1163-1170 (Pubitemid 40279249)
21. Krause K., Karger S., Gimm O., Sheu S.Y., Dralle H., Tannapfel A., Schmid K.W., Dupuy C., Fuhrer D. 2007 Characterisation of DEHAL1 expression in thyroid pathologies. Eur J Endocrinol 156:295-301 (Pubitemid 46554496)
22. Krause K., Eszlinger M., Gimm O., Karger S., Engelhardt C., Dralle H., Fuhrer D. 2008 TFF3-based candidate gene discrimination of benign and malignant thyroid tumors in a region with borderline iodine deficiency. J Clin Endocrinol Metab 93:1390-1393 (Pubitemid 351519738)
23. Fernández de Mattos S., Villalonga P., Clardy J., Lam E.W. 2008 FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther 7:3237-3246
24. Klagge A., Krause K., Müller K., Haag J., Fuhrer D. 2010 High-efficient non-viral transfection of the Rat 1 thyroid cell line FRTL-5. Horm Metab Res 42:897-899
25. Weng L.P., Gimm O., Kum J.B., Smith W.M., Zhou XP, Wynford- Thomas D, Leone G, Eng C 2001 Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum Mol Genet 10:251-258
26. Klagge A., Weidinger C., Krause K., Jessnitzer B., Gutknecht M., Fuhrer D. 28 June 2011 The role of FOXO3 in DNA damage response in thyrocytes. Endocr Relat Cancer 10.1530/ERC-11-0138
27. Jung H.S., Kim D.W., Jo Y.S., Chung H.K., Song J.H., Park J.S., Park K.C., Park S.H., Hwang J.H., Jo K.W., Shong M. 2005 Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol 19:2748-2759 (Pubitemid 41577247)
28. Mrozek E., Kloos R.T., Ringel M.D., Kresty L., Snider P., Arbogast D., Kies M., Munden R., Busaidy N., Klein M.J., Sherman S.I., Shah M.H. 2006 Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91:2201-2204 (Pubitemid 43855005)